Educational Webinars

Understanding Statistical and Clinical Significance

Presenters: Dr. Jinsy Andrews (Columbia University), Dr. Christina Fournier (Emory University), Dr. Eric Macklin (Mass General Hospital)

What do researchers and scientists mean when they describe a study as “statistically…

Palliative care for people with ALS

Presenter: Ambereen K. Mehta, MD, MPH, FAAHPM, Johns Hopkins University

In this webinar, we will review what palliative care is and how it can support the quality of life for people living with ALS. We’ll discuss the role of…

Why lumbar puncture and CSF biomarkers are important to ALS therapeutic development

Presenter: Nicholas J. Maragakis, M.D., Johns Hopkins University

The development of biomarkers for understanding ALS progression and for establishing therapeutic target engagement is at a critical stage. As new therapies are…

The ALS Association Webinar: Implications of tofersen for everyone with ALS

The FDA’s recent decision to approve tofersen offers direct benefit to people living with SOD1 ALS, and offers hope to everyone else living with ALS as well. Join the team from The ALS Association to discuss the implications of this…

Tofersen Update

The U.S. Food and Drug Administration (FDA) has granted accelerated approval for tofersen for the treatment of individuals with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). Join Dr. Timothy Miller for a webinar…

NEALS Webinar: An Update on Tofersen

Please join us for a webinar update on tofersen moderated by NEALS Co-Chair Dr. Jinsy Andrews. Dr. Timothy Miller will provide background on tofersen and updates from the March 22nd FDA Advisory Committee Meeting. Holly Fernandez Lynch,…

Phase 2 Trial of AP-101 in SOD1 and Sporadic ALS

Dr. Angela Genge (Montreal Neurological Institute-Hospital) discusses the research behind AP-101 and provides an overview of the trial and what study participation involves. The phase 2 trial of AP-101 is currently enrolling…

ALSUntangled – Vitamins and Supplements in ALS

In this webinar, Dr. Bedlack will review ALSUntangled, including how patients and families can use it to make more informed decisions about vitamins and supplements. He will show how he guides patients at Duke who want to…

Update on COURAGE-ALS: A Phase 3 Trial of Reldesemtiv, a Muscle Directed Drug

Speaker: Dr. Jeremy Shefner (Barrow Neurological Institute)An update on the currently enrolling COURAGE-ALS trial will be provided. This will include results of the first interim analysis, a review of the novel mechanism of action for…

Trials of the Future: Remote Monitoring

Speakers: Dr. Christina Fournier (Emory University), Dr. Andrew Geronimo (Penn State Health), and Dr. Eufrosina Young (SUNY Upstate)

Join us for a webinar on remote monitoring for clinical care moderated by NEALS Co-Chair Dr.…